Scolaris Content Display Scolaris Content Display

Epidermal growth factor receptor blockers for the treatment of ovarian cancer

Esta versión no es la más reciente

(A) The EGFR is a transmembrane protein. (B) Following binding to its ligand, EGF, the EGFR is stimulated and develops tyrosine kinase activity. (C) Tyrosine kinase activity sets of a sequence of downstream events that lead to stimulation of cell growth. (D) EGFR activity can be blocked by antibodies, which prevent EGF binding to the receptor, or using chemicals, which inhibit the tyrosine kinase enzyme activity.
Figuras y tablas -
Figure 1

(A) The EGFR is a transmembrane protein. (B) Following binding to its ligand, EGF, the EGFR is stimulated and develops tyrosine kinase activity. (C) Tyrosine kinase activity sets of a sequence of downstream events that lead to stimulation of cell growth. (D) EGFR activity can be blocked by antibodies, which prevent EGF binding to the receptor, or using chemicals, which inhibit the tyrosine kinase enzyme activity.